Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.

1. The clinical use of the antitumour agent, doxorubicin, is largely limited by the development of a cumulative dose-related cardiotoxicity. This toxicity is generally believed to be caused by the formation of oxygen free radicals. In earlier studies it was established that flavonoids, naturally occ...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: van Acker, S. A., Kramer, K., Grimbergen, J. A., van den Berg, D. J., van der Vijgh, W. J., Bast, A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 1995
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1908788/
https://ncbi.nlm.nih.gov/pubmed/7582554
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller